Search Videos and More
Course
Devices Can Play a Key Role in Managing Heart Failure
Even with gold-standard treatment, heart failure causes tremendous distress in patients, with debilitating symptoms and pain that can impact their day-to-day functioning, social relationships, and mental health. Studies have found that the quality of life for heart failure patients is comparable to people on dialysis, and five-year survival estimates are on par with some cancers.
Course
The Latest in CTEPH Diagnosis and Treatment
Research has shown that around 3.8% of patients with pulmonary embolism go on to develop chronic thromboembolic pulmonary hypertension (CTEPH). But what are the risk factors, and how can providers best manage these patients?
Course
2025 GOLD International COPD Conference
Hosted in partnership by The Temple Lung Center and the Global Initiative for Chronic Obstructive Lung Disease (GOLD), this conference will be presented in a hybrid format with in-person sessions virtually simulcast to a global audience of healthcare providers involved in the care and management of people with COPD. Learn alongside other dedicated COPD practitioners, and hear directly from leading experts and researchers.
News
Temple Lung Center: Advances in Lung Care and Research in 2024
The Temple Lung Center continued to set the standard in lung health throughout 2024, delivering exceptional clinical care and advancing lung disease research. Through expanded screening programs and innovative clinical trials, our multidisciplinary team—including pulmonologists, thoracic surgeons, and other specialists—provided patients with breakthrough options for diagnosing and treating even the most complex lung conditions.
News
Temple Lung Center | Enrolling Clinical Trials
The Temple Lung Center conducts one of the most comprehensive lung disease clinical trials programs in the country. Our advancements in basic, translational and clinical research are changing lung disease treatment. By pioneering effective therapies, we bring hope to patients with serious and debilitating lung diseases.
Course
Evaluation of Dyspnea
Dyspnea and dyspnea on exertion are among the most common patient complaints both in the office and in the hospital setting. While in-hospital evaluations tend to have a more acute focus, outpatient office evaluations of dyspnea tend to be more varied and nuanced in their etiology. Pulmonary function testing and cardiopulmonary exercise testing are important modalities to help differentiate causes of dyspnea.
Course
Cardiotoxic Therapies in Cancer Treatment: What Providers Need to Know
Thanks to advances in treatment, more people are surviving cancer and living into their 60s, 70s, and beyond. But with this increase in survival has also come an increase in cardiovascular disease for this population. As a result, providers must keep cardiotoxicity in mind as they implement treatment plans for their patients, says Eman Hamad, MD, director of Cardio-Oncology and the Advanced Heart Failure and Transplant Program at Temple University Hospital.
Course
Interstitial Lung Disease (ILD) and Associated Pulmonary Hypertension
Interstitial lung disease (ILD) is a commonly encountered disease state. Patients who develop ILD associated with pulmonary hypertension have an increased mortality risk. This program aims to review the classification of commonly encountered interstitial lung diseases. Secondly, to describe the pathophysiology that leads to the development of ILD associated pulmonary hypertension. Lastly, to review a diagnostic approach to ILD associated pulmonary hypertension along with treatment options.
Course
Cardiac Amyloidosis: What Providers Should Know About Screening, Diagnosis, and Treatment
Over the past two decades, there has been a significant increase in both the incidence and prevalence of cardiac amyloidosis. This is most likely due to improved screening and diagnosis. However, even with these advances, delayed diagnosis is common. Diagnosis typically takes two years for patients with amyloid light-chain amyloidosis (AL), and up to 7.2 years for those with transthyretin amyloidosis (ATTR), explains Temple heart failure cardiologist Carly Fabrizio, DO.
News
Temple Lung Center: Advancing Research in COPD
The Temple Lung Center is one of the world’s largest COPD research centers, and has demonstrated its commitment to offer innovative therapies to patients by applying research breakthroughs to clinical care.
Video
Lung Transplantation for COPD Patients
Chronic Obstructive Pulmonary Disease (COPD) is the sixth leading cause of death in the U.S., affecting nearly 16 million adults. Dr. Gerard Criner, Director of the Temple Lung Center, recently joined the Global Forum on Lung Transplantation to explore the role of lung transplantation for COPD.
News
November Quarterly Impact Report: The Temple Healthy Chest Initiative
The American Cancer Society is forecasting more than two million new cases of cancer to be diagnosed in the year 2024. And while the incidence rate is on the rise, cancer-related deaths continue to decline. Early detection is key to producing better outcomes for patients.